Previous Close | 2.2700 |
Open | 2.2800 |
Bid | 2.2500 x 1400 |
Ask | 2.3000 x 2200 |
Day's Range | 2.2100 - 2.3156 |
52 Week Range | 2.0000 - 6.6200 |
Volume | |
Avg. Volume | 121,721 |
Market Cap | 64.981M |
Beta (5Y Monthly) | 1.25 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7220 |
Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.17 |
Subscribe to Yahoo Finance Plus to view Fair Value for LIFE
Symposia presentation to highlight significant advancements in understanding of efzofitimod’s MOA Poster presentation analyzing exposure-efficacy of efzofitimod further supports clinical proof-of-concept SAN DIEGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data on the me
Patent highlights potential benefit of efzofitimod as a combination therapy for IPF standard of care.SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a Notice of Allowance for a patent covering methods for the use of histidyl-tRNA synthetase (HARS) Fc fusion pr
Global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in EuropeSAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of sarcoidosis based on the opinion of